New pill targets cancer growth at the genetic level

NCT ID NCT07692776

Not yet recruiting Disease control Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYH2095 (a KAT6A/B inhibitor taken as a daily oral tablet)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial, so the drug may prove unsafe or ineffective. Side effects are unknown, and it is only tested in a small number of people with advanced disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjing, 300060, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.